Natco Pharma transfers Lenalidomide ANDA to Arrow International
Hyderabad: Natco Pharma Limited has recently announced that the company has transferred the Lenalidomide Capsules ANDA (2.5mg, 5mg, l0mg, l5mg, 20mg and 25mg strengths) to Arrow International Limited as per an earlier agreement between the parties.
This transfer of the ANDA to Arrow does not materially change any of the terms of the agreement between the parties.
Arrow International Limited (an affiliate of Teva Pharmaceutical Industries Ltd) is the marketing partner of NATCO for this product in the US market.
The ANDA was approved by U.S. Food and Drug Administration (USFDA) in May 2021 with final approval in the 5mg, l0mg, l5mg, and 25mg strengths, and tentative approval in the 2.5mg and 20mg strengths.
Read also: Natco Pharma marketing partner gets USFDA nod for Carfilzomib Vials ANDA
Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million.
The Company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc
